3 March 2025

GENinCode Plc

("GENinCode" or the "Company")

Result of General Meeting, Issue of Equity and Total Voting Rights

GENinCode plc (AIM: GENI), the genetics company focused on the prevention of cardiovascular disease ("CVD") and the early detection of ovarian cancer, announces that all resolutions put to Shareholders at the General Meeting held earlier today in connection with the placing, subscription and retail offer announced by the Company on 14 February 2025 were duly passed.

(1)     Any proxy appointments, which gave discretion to the Chairman have been included in the 'For' votes total.

(2)     Votes "For" and "Against" any resolution are expressed as a percentage of votes validly cast for that resolution.

(3)     A vote "Withheld" is not a vote in law and is not counted in the calculation of the percentage of shares voted "For" or "Against", nor in the aggregate figure of total votes cast.

Subscription by the Nestor Oller entities

The Company has been notified by Nestor Oller, a significant shareholder in the Company, of a change in the legal entity subscribing for 9,459,460 shares, transferring from Bobby Jean SICAV S.A. to Santi-1990 SL. Both entities are undertakings controlled by Nestor Oller.

Issue of Equity and Total Voting Rights

Following shareholder approval at the general meeting and conditional on admission, 88,040,541 new ordinary shares have been allotted pursuant to the Placing, 1,809,508 new ordinary shares pursuant to the Retail Offer and 20,067,567 pursuant to the Subscription.

The Company has therefore allotted a total of 109,917,616 new ordinary shares in connection with the Fundraising.

Admission is expected to take place at 8.00 a.m. on or around 4 March 2025.

Following Admission, the total number of Ordinary Shares in the capital of the Company in issue will be 286,882,042 with each Ordinary Share carrying the right to one vote. There are no shares held in treasury and therefore, following Admission, the total number of voting rights in the Company will be 286,882,042.

The above figure may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure, Guidance and Transparency Rules.

Capitalised terms used in this announcement have the meaning given to them in the announcement of the Placing and Subscription dated 14 February 2025, unless otherwise defined in this announcement.

Enquiries: